RGS10 Deficiency Facilitates Distant Metastasis by Inducing Epithelial-mesenchymal Transition in Breast Cancer

Overview

Journal Elife

Specialty Biology

Date 2024 Aug 15

PMID 39145770

Authors

Yang Liu

Yi Jiang

Peng Qiu

Tie Ma

Yang Bai

Jiawen Bu

Yueting Hu

Ming Jin

Tong Zhu

Xi Gu

Affiliations

Soon will be listed here.

Abstract

Distant metastasis is the major cause of death in patients with breast cancer. Epithelial-mesenchymal transition (EMT) contributes to breast cancer metastasis. Regulator of G protein-signaling (RGS) proteins modulates metastasis in various cancers. This study identified a novel role for RGS10 in EMT and metastasis in breast cancer. RGS10 protein levels were significantly lower in breast cancer tissues compared to normal breast tissues, and deficiency in RGS10 protein predicted a worse prognosis in patients with breast cancer. RGS10 protein levels were lower in the highly aggressive cell line MDA-MB-231 than in the poorly aggressive, less invasive cell lines MCF7 and SKBR3. Silencing in SKBR3 cells enhanced EMT and caused SKBR3 cell migration and invasion. The ability of RGS10 to suppress EMT and metastasis in breast cancer was dependent on lipocalin-2 and . These findings identify RGS10 as a tumor suppressor, prognostic biomarker, and potential therapeutic target for breast cancer.

References

Santiago-Sanchez G, Pita-Grisanti V, Quinones-Diaz B, Gumpper K, Cruz-Monserrate Z, Vivas-Mejia P . Biological Functions and Therapeutic Potential of Lipocalin 2 in Cancer. Int J Mol Sci. 2020; 21(12). PMC: 7352275. DOI: 10.3390/ijms21124365. View

Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov J . Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011; 27(12):1739-40. PMC: 3106198. DOI: 10.1093/bioinformatics/btr260. View

Bianchini G, Balko J, Mayer I, Sanders M, Gianni L . Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016; 13(11):674-690. PMC: 5461122. DOI: 10.1038/nrclinonc.2016.66. View

Wang Z, Chen J, Wang S, Sun Z, Lei Z, Zhang H . RGS6 suppresses TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancers via a novel mechanism dependent on its interaction with SMAD4. Cell Death Dis. 2022; 13(7):656. PMC: 9334288. DOI: 10.1038/s41419-022-05093-0. View

Yin W, Wang P, Wang X, Song W, Cui X, Yu H . Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells. Braz J Med Biol Res. 2013; 46(6):546-54. PMC: 3854438. DOI: 10.1590/1414-431X20131662. View

Lee A, Oesterreich S, Davidson N . MCF-7 cells--changing the course of breast cancer research and care for 45 years. J Natl Cancer Inst. 2015; 107(7). DOI: 10.1093/jnci/djv073. View

Singh S, Chakrabarti R . Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells. J Clin Med. 2019; 8(5). PMC: 6572359. DOI: 10.3390/jcm8050642. View

Morales-Valencia J, Lau L, Marti-Nin T, Ozerdem U, David G . Therapy-induced senescence promotes breast cancer cells plasticity by inducing Lipocalin-2 expression. Oncogene. 2022; 41(38):4361-4370. PMC: 9482949. DOI: 10.1038/s41388-022-02433-4. View

Gyorffy B . Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021; 19:4101-4109. PMC: 8339292. DOI: 10.1016/j.csbj.2021.07.014. View

10.

Li C, Chu P, Yiang G, Wu M . The Molecular Mechanism of Epithelial-Mesenchymal Transition for Breast Carcinogenesis. Biomolecules. 2019; 9(9). PMC: 6770718. DOI: 10.3390/biom9090476. View

11.

Cai F, Chen L, Sun Y, He C, Fu D, Tang J . MiR-539 inhibits the malignant behavior of breast cancer cells by targeting SP1. Biochem Cell Biol. 2019; 98(3):426-433. DOI: 10.1139/bcb-2019-0111. View

12.

Huang Y, Hong W, Wei X . The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022; 15(1):129. PMC: 9461252. DOI: 10.1186/s13045-022-01347-8. View

13.

Hooks S, Murph M . Cellular deficiency in the RGS10 protein facilitates chemoresistant ovarian cancer. Future Med Chem. 2015; 7(12):1483-9. PMC: 4597593. DOI: 10.4155/fmc.15.81. View

14.

Steeg P . New insights into the tumor metastatic process revealed by gene expression profiling. Am J Pathol. 2005; 166(5):1291-4. PMC: 1606385. DOI: 10.1016/S0002-9440(10)62348-6. View

15.

Coates A, Winer E, Goldhirsch A, Gelber R, Gnant M, Piccart-Gebhart M . Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26(8):1533-46. PMC: 4511219. DOI: 10.1093/annonc/mdv221. View

16.

Gorecki I, Rak B . The role of microRNAs in epithelial to mesenchymal transition and cancers; focusing on mir-200 family. Cancer Treat Res Commun. 2021; 28:100385. DOI: 10.1016/j.ctarc.2021.100385. View

17.

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J . STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014; 43(Database issue):D447-52. PMC: 4383874. DOI: 10.1093/nar/gku1003. View

18.

Yang J, Bielenberg D, Rodig S, Doiron R, Clifton M, Kung A . Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A. 2009; 106(10):3913-8. PMC: 2656179. DOI: 10.1073/pnas.0810617106. View

19.

Wen L, Li J, Guo H, Liu X, Zheng S, Zhang D . Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients. Cell Res. 2015; 25(12):1376. PMC: 4670997. DOI: 10.1038/cr.2015.141. View

20.

Chaudhury S, OConnor C, Canete A, Bittencourt-Silvestre J, Sarrou E, Prendergast A . Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias. Nat Commun. 2018; 9(1):5280. PMC: 6290074. DOI: 10.1038/s41467-018-07584-1. View